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Abstract Skeletal muscle innervation is a multi-step process
leading to the neuromuscular junction (NMJ) apparatus
formation. The transmission of the signal from nerve to
muscle occurs at the NMJ level. The molecular mecha-
nism that orchestrates the organization and functioning of
synapses is highly complex, and it has not been
completely elucidated so far. Neuromuscular junctions
are assembled on the muscle fibers at very precise
locations called end plates (EP). Acetylcholine receptor
(AChR) clusterization at the end plates is required for an
accurate synaptic transmission. This review will focus
on some mechanisms responsible for accomplishing
the correct distribution of AChRs at the synapses. Re<
cent evidences support the concept that a dual trans<
criptional control of AChR genes in subsynaptic and
extrasynaptic nuclei is crucial for AChR clusterization.
Moreover, new players have been discovered in the
agrin–MuSK pathway, the master organizer of postsynap-
tical differentiation. Mutations in this pathway cause
neuromuscular congenital disorders. Alterations of the
postynaptic apparatus are also present in physiological
conditions characterized by skeletal muscle wasting.
Indeed, recent evidences demonstrate how NMJ misfunc-
tioning has a crucial role at the onset of age-associated
sarcopenia.
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1 Introduction
Motor neuron innervation is the most relevant maturation
event in skeletal muscle development sincemuscle physiology,
also accounting for locomotion and breath, depends on it.
Innervation implies sophisticated interactions between motor
neuron axons and end plates on the muscle fibers, thus
resulting in a development of highly elaborated synapses
called neuromuscular junctions (NMJs). As soon as the action
potential reaches the axon terminals, it induces the opening of
the voltage-gated Ca2+ channels on the presynaptic nerve
membrane. This allows a Ca2+ influx that induces synaptic
vescicles to fuse with the presynaptic membrane and to
release the neurotransmitter acetylcholine (ACh) in the
synaptic cleft. From here, ACh diffuses and binds to
acetylcoline receptors (AChRs) localized on the post-
synaptic membrane on the muscle fiber. This binding
makes AChRs permeable to both Na+ and K+ and opens
the associated voltage-gated Na+ channels on the muscle
membrane which, in turn, initiate an action potential causing
Ca2+ release from the sarcoplasmic reticulum into the cytosol
and muscle contraction. Acetylcholinesterase, located on the
synaptic portion of the basal lamina that envelops muscle
fibers, quickly inactivates ACh released from the presynaptic
membrane so that the ACh concentration in the synaptic cleft
decreases rapidly and neurotransmission stops. The correct
nerve–muscle impulse transmission requires an intricate
network of interacting signaling pathways displaying a
certain rate of redundancy, which is, however, necessary to
ensure the process’s spatial and temporal accuracy.
Defects in the signaling pathways that regulate NMJ
differentiation and functioning lead to a variety of congenital
neuromuscular disorders termed congenital myasthenic syn-
dromes (CMS), typified by muscle weakness and fatigue [1].
Loss of the nerve signaling caused by the degeneration of
motor neurons leads to a debilitating loss of muscle mass,
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atrophy, and paralysis. Also, aging and diseases such as
cancer, AIDS, and chronic heart failure are physical
conditions in which NMJ normal activity, muscle mass,
and function are highly compromised. For these reasons,
understanding the molecular basis of neuromuscular synapse
functioning is fundamental to such disorders’ therapeutic
approach. This review will focus on the development of the
postsynaptic apparatus and will highlight the role of some
defects of this process which are at the onset of neuromus-
cular disease and muscle wasting-associated pathologies.
2 NMJ formation
NMJs do not develop at random locations in muscles;
rather, they are assembled in a narrow central region of the
muscle fiber, so that many NMJs are located in a row,
forming an end plate across the fiber. Each NMJ consists of
an area of apposition between a motoneuron axon branch
and a single multinucleated muscle fiber. AChRs localize
on the postsynaptic muscle membrane, and their spatial
distribution is critical for synaptic function. A high density
of AChRs at synapses is required to initiate a synaptic
action potential in the myofiber. Vice versa, around
synapses and in the rest of the fiber, the density of AChRs
has to be kept low in order to allow a complete maturation
of the NMJ. When myoblasts fuse to form myotubes,
AChR subunits are assembled into the membrane at a very
low density (1,000 μm−2). In mature synapses, AChRs
accumulate at a density >10,000 μm−2directly beneath the
motor nerve terminal while they drop to <10 μm−2 in the
extrasynaptic membrane [2, 3].
A puzzling question about the developing postsynaptic
structure is whether the motoneurons or the muscle fibers
determine where and how the NMJs are formed. The motor
nerve might initiate AChR cluster formation (neurocentric
model) or clusters might form aneurally and then recog-
nized by the nerve (myocentric model) [4]. Some studies
indicate that the primitive AChR clusterization is nerve
independent, while the nerve induces only maturation and
enlargement of some of the primitive aneural AChR clusters.
During early mouse embryogenesis, between embryonic
day 12.5 (E12.5) and E14.5, aneural muscle fibers begin
spontaneously to accumulate AChRs in a central region where
innervation will occur (prepatterning) [5–9]. This phenome-
non also occurs in mutant mice where motor axons fail to
contact skeletal muscle [10]. Following such nerve-
independent AChR clustering, nerve terminals overlap some
prepatterned AChR clusters and, at E18.5, the innervated
clusters are enlarged, whereas the other primitive clusters
disappear in synaptic and extrasynaptic regions [8, 9].
Conversely, other studies in cultured myotubes have indicated
that motor neurons induce postsynaptic differentiation ignoring
preexisting aneural clusters [11, 12]. It has also been recently
hypothesized that some already formed AChR clusters are
recognized by the nerve on muscle fibers, while others are
induced by motor axons [13]. It is also possible that the
myogenic and the neurogenic component role might depend
on the species and on the developmental context, although the
topic keeps being highly controversial [14].
3 NMJ maturation and AChR clusterization
The mechanisms that lead to the clusterization of ACh
receptors within the postsynaptic membrane require a precise
interaction of signals among motoneurons and skeletal muscle
fibers and occur through different modalities. It has been
described that AChRsmove from the extrasynaptic region and
are trapped to the synaptic pool through a rapid lateral
diffusion [2]. Clustering also induces a higher stability of the
AChRs; at early stages of development, the half-life of
junctional non-clustered AChRs is about 1 day, whereas in
adult, is increased to 8–14 days [15]. Moreover, transcrip-
tional regulation has a pivotal role in AChR clusterization.
Nuclei that are associated at the postsynaptic membrane
(synaptic nuclei) actively transcribe the AChR subunit genes
and other postsynaptic component genes at a higher rate than
the non-synaptic nuclei. This leads to a localized synthesis
and accumulation of AChRs [16–19]. The formation of
AChR clusters depends not only on positive signals that
enhance AChR concentration in the synaptic area but also on
negative signals necessary to decrease AChR concentration
outside the synaptic area, along the entire fiber.
3.1 Positive signaling
The best characterized signaling responsible for AChR
accumulation at the NMJs is the agrin/lipoprotein receptor-
related protein 4 (Lrp4)/muscle-specific tyrosine kinase
receptor (MuSK) pathway. Agrin is a large heparan sulfate
proteoglycan first isolated from the Torpedo electric organ
[20] synthesized in the motoneurons, transported along axons,
and released in the synaptic basal lamina, which surrounds the
muscle fiber [21]. Agrin is necessary for clustering AChRs at
synaptic sites (Fig. 1a). Agrin is sufficient to induce AChR
ectopic clusters in adult muscle and postsynaptic specializa-
tion in denervated fibers [22, 23]. Although it is not essential
for prepatterning, in agrin−/−mice, NMJs and AChRs are
uniformly distributed in the muscle fiber and not clustered
[8, 9, 24], and postsynaptic differentiation is inhibited.
Agrin acts by activating another important player in the
NMJ assembly pathway, MuSK. MuSK is a tyrosine kinase
receptor expressed in the postsynaptic membrane of NMJs
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[25] where it co-localizes with AChRs [26]. The main role of
agrin is to initiate MuSK autophosphorylation and activation
[27] (Fig. 1a). However, MuSK can also be activated in an
agrin-independent manner [28]. Indeed, in MuSK−/−fibers,
no NMJs are formed, and also, prepatterning before
innervation is absent [8, 9, 29]. Like AChR, MuSK gene is
a target for the transcription factor myogenin (see below).
Myogenin mediates MuSK upregulation during muscle fiber
denervation and MuSK downregulation upon innervation
[30]. However, upon innervation, in the synaptic nuclei,
MuSK is upregulated by different transcriptional pathways.
Although agrin stimulates MuSK phosphorylation, the two
proteins do not interact directly, but additional proteins
(coreceptors) are engaged to allow agrin-mediated signaling
in myotubes [31, 32]. A recently discovered agrin coreceptor
is the transmembrane protein Lrp4 [33]. Lrp4 is concentrated
at the NMJs and is necessary for agrin-stimulated MuSK
phosphorylation and AChR clustering. According to this
model, Lrp4 self-associates and interacts with MuSK in the
absence of agrin. When agrin binds to this preformed
complex, it triggers a reorganization of MuSK, so promoting
its transphophorylation and kinase activity. Once phopshory-
lated, MuSK activates signaling pathways that lead to
synaptic differentiation including clustering of AChRs [34,
35] (Fig. 1a). Agrin activation of MuSK also leads to
concentration at synapses of other proteins such as acetyl-
cholinesterase (AChE), rapsyn, and neuregulin (NRG)
receptors (ErbBs; see below). Moreover, Lrp4 has a crucial
role in muscle prepatterning since it promotes MuSK
phosphorylation and activation in the absence of agrin [36].
Once phosphorylated, MuSK recruits docking protein-7
(Dok-7), a non-catalytic adapter protein, which stimulates
further MuSK phosphorylation and increases MuSK kinase
activity (Fig. 1a). To properly regulate NMJ formation,
Dok-7 engages at two phosphorylation sites two adapter
proteins, Crk and CrkL. In mouse models lacking Dok-7,
Crk, and CrkL, neuromuscular synapse fails to form [37–40].
A coeffector in AChR assembly is rapsyn, a membrane
protein associated with the cytoplasmic side of the plasma
membrane (Fig. 1a). Rapsyn anchorates AChRs at the
muscle membrane from the earliest stages of synapto-
genesis, including prepatterning [41]. Rapsyn also interacts
with cytoskeletal proteins, thus being essential for AChR
clustering. In mice lacking rapsyn, AChRs fail to aggregate
[42]. It has been proposed that MuSK induces phosphoryla-
tion of nascent AChR clusters and promotes also the binding
of additional rapsyn to AChR aggregates, which contributes to
AChR cluster growth and stability. Rapsyn may function as a
scaffolding protein presenting a MuSK-activated Src-related
kinase to the AChRs [43].
Upon phosphorylation and activation, MuSK interacts
with a large number of effectors and pathways converging
toward the regulation of AChR clusterization through
different mechanisms. MuSK indeed controls (1) AChR
scaffolding and redistribution via actin cytoskeleton reor-
ganization, (2) AChR stabilization through AChR phos-
phorylation, (3) its proper endocytosis and turnover are also
important for AChR clustering, and (4) enhancement of
transcription of AChR genes selectively in subsynaptic
nuclei (reviewed in [14]).
AChR subunits are selectively transcribed in the synaptic
nuclei of myofibers. mRNAs encoding other synaptic
proteins such as AChE, MuSK, and rapsyn are also
concentrated at the synapses. The pathway activating AChR
transcription in the subsynaptic regions still remains
unclear. One candidate activator is neuregulin-1 (NGR-1),
a glycoprotein which works as an extracellular signal that
stimulates AChR and other synapse-specific components
transcription. NRG-1 acts by binding to membrane-
associated tyrosine kinase receptors related to the EGF
receptor (erbB proteins 2-3-4) [44] (Fig. 1b). In vivo studies
on NGR-1 role in NMJ differentiation are difficult because
nrg-1−/−embryos die far before NMJs start forming. Hetero-
zygous mice are viable and fertile and show a decreased
number of AChRs at the NMJs [45, 46]. However, some
recent in vivo studies, in which neuregulin-1 and erbB
proteins were conditionally deleted, demonstrated that
neuregulin signaling is dispensable [47, 48]. For this reason,
the idea that NRG-1 is the main signal responsible for the
increased transcription of AChRs is highly controversial.
Recent evidences also indicate that neuregulin may have a
role in AChR clustering and trafficking by modulating rather
than determining AChR expression at the NMJs [49].
The pathways leading from NRG-1–ErbB binding to
regulation of AChR gene transcription have been identified.
Both in cultured muscle cells and in vivo, ErbB phosphory-
lation by NRG-1 concomitantly stimulates ERK [50, 51] and
the c-JUN N-terminal kinase (JNK) activity [52, 53]. The
activation of these pathways results in increased levels and
phosphorylation of the E-twenty-six (ETS)-domain-binding
transcription factor GA-binding protein (GABP)-α which
binds DNA, heterodimerizes with GABP-β, and increases
AChR transcription [54, 55] (Fig. 1b). ETS transcription
factors bind DNA at the N-box, a DNA element located not
only on the AChR promoter but also on the promotor of
other NMJ components (utrophin and acelylcholinesterase)
[56–58]. In vivo inhibition of GABP results in reduced
expression of AChRs [59] indicating the GABP signaling
pathway, activated directly or indirectly by neuregulin, is
necessary for the formation of functional synapses. As stated
before, the agrin–MuSK pathway also contributes to increase
synaptic AChR gene transcription by a NRG/ErbB-indepen-
dent but Rac-dependent JNK activation (Fig. 1b) and also by
interacting with the NRG/ErbB pathway [43, 60, 61].
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3.2 Negative signals
The positive signals we described enhance AChR accumu-
lation only in the synaptic area. To achieve a correct
formation of AChR clusters in the NMJs, the presence of
some negative signals that decrease AChR concentration in
the rest of the fiber, in non-synaptic areas, is necessary.
Muscle depolarization induced by released ACh is a
negative signal for AChRs. It inhibits AChR localization,
stability [62], and transcription along the muscle fiber by
stimulation of cyclin-dependent kinase 5 [63, 64], protein
kinase C (PKC), and Ca2+/calmodulin-dependent kinase II
(CaMKII) [65]. Indeed, mutant mice lacking acetyltransferase,
a biosynthetic enzyme for ACh, develop faster and larger
AChR clusters; they also exhibit hyperinnervation due to a
broader distribution of AChR clusters along the muscle fiber
[66, 67].
In detail, through muscle action potential, ACh induces
downregulation of AChR transcription along the entire fiber.
However, since the previously described positive signals
enhance AChR accumulation only in the synaptic area
(Fig. 1), this results in a ACh-dependent suppression of
AChR subunit gene transcription in extrasynaptic nuclei
(Fig. 2) [68]. Suppression of AChR transcription occurs
through myogenin inhibition. Myogenin is a basic helix-
loop-helix myogenic transcription factor that activates AChR
genes in the absence of innervation or by blockade of muscle
electrical activity by denervation [69]. Myogenin regulates
AChR and many other muscle gene transcription by binding
the E-boxes located on their promoter/enhancers. Myogenin
is downregulated as the muscle matures around the time
when innervation is completed, and it is upregulated upon
denervation [70]. Forced expression of myogenin in vivo is
able to induce AChR expression along the entire muscle
fiber [71]. Multiple mechanisms have been proposed to
explain how neural activity controls myogenin in postnatal
muscle. On the basis of one of these mechanisms, following
muscle depolarization, extracellular calcium enters through
voltage-activated channels and activates different signal
transduction cascades mediated by PKC and CaMKII,
leading to myogenin phosphorylation [63, 72]. This post-
translational modification inhibits myogenin binding to E-
boxes of AChR promoters, resulting in reduced AChR
expression (Fig. 2) [73, 74]. A second regulatory mechanism
restraining myogenin activity involves transcriptional repres-
sion of myogenin (Fig. 2). The posttranslational and the
transcriptional mechanisms of myogenin repression could act
on a different timescale to ensure that myogenin expression
remains blocked as long as the muscle is innervated [30].
Although it is very well known that myogenin is transcrip-
tionally modulated as a consequence of muscle depolariza-
tion, the mechanisms that are upstream of this regulation
have only recently started to be elucidated. Several studies
reported that in myogenin repression during innervation,
class II deacetylases are recruited at the myogenin promoter.
The hystone deacetylase 9 (HDAC9) splice variant MITR is
a transcriptional repressor induced in innervated muscle. It
contributes to myogenin repression by chromatin acetylation
and acts as a corepressor in a complex with the myocyte
enhancer factor-2 (MEF2) transcription factor (Fig. 2) [75].
Another myogenin repressor is dachshund homolog 2
(DACH2) (Fig. 2). It has been shown that, during denerva-
tion, DACH2 is inhibited by HDAC4, another class II
deacetylase, which induces myogenin expression thereby
activating AChRs [76–78]. A third circuit of postnatal
myogenin expression regulation is mediated by MSY3/
CsdA, a Y-box factor that binds the myogenin promoter at
a new binding motif (highly conserved element, HCE) and
exerts a repression function (Fig. 2). MSY-3 is therefore
partially responsible for the restricted spatiotemporal expres-
sion of AChR in the subsynaptical regions of muscle fibers
[79]. The conserved binding motifs of HDAC9/MEF2,
DACH2, and MSY-3 are adjacent sequences on the
myogenin promoter, which suggests a strong interplay
between the three cis–trans systems to ensure a proper
myogenin and AChR repression in adult and innervated
muscle.
In conclusion, while during development the first events
leading to AChR clusterization are MuSK- and rapsyn-
dependent but nerve-independent (AChR prepatterning), the
stabilization of some prepatterned AChR clusters requires the
innervation. Indeed, once the muscle is contacted by the
nerve, ACh released by the motor neuron induces a
postsynaptic potential which stabilizes previous AChR
clusters in the contacted area and prevents AChR clustering
in non-contacted area. Moreover, agrin released by the neuron
also stabilizes the AChR clusters and, as well as neuregulin,
strongly increases AChR transcription in subsynaptic nuclei
(Fig. 1). Concomitantly, Ca2+-dependent signals triggered by
Fig. 1 The agrin–MuSK–Lrp4 and neuregulin–ErbB pathways induce
NMJ assembly positive signals. a Agrin is released by the motor axon
terminal and induces AChR clustering, phosphorylation, and stabili-
zation at the postsynaptic membrane. Lrp4 associates with MuSK in
the absence of agrin. Agrin binds to the preformed MuSK–Lrp4
complex by interacting with Lrp4 and promotes MuSK transphos-
phorylation and activation. Once phosphorylated, MuSK recruits the
adapter protein Dok-7 which binds Crk and CrkL and stimulates
further MuSK phosphorylation and kinase activity. This induces
phosphorylation and stabilization of nascent AChR clusters. Rapsyn
is a coeffector in AChR assembly which anchorates AChRs at the
muscle membrane. b Neuregulin (NGR-1) is released by the nerve and
induces AChR transcription in synaptic nuclei. NRG-1 acts by binding
tyrosine kinases receptors ErbBs. ErbB phosphorylation induced by
NRG stimulates ERK and JNK kinase activity which phosphorylates
GABP-α and GABP-β transcription factors. GABP-α heterodimerizes
with GABP-β and binds DNA at the N-box thereby enhancing
transcription of AChR genes

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nerve-induced muscle electrical activity cause myogenin
downregulation and inhibition of AChR transcription in
extrasynaptic regions of the muscle fiber (Fig. 2). The
integration of these two mechanisms makes possible the
compartmentalization of AChR gene expression in subsynap-
tic nuclei and the stabilization of AChR clusters only at NMJs.
4 Neuromuscular disorders associated to defects
in synaptogenesis
When NMJs are severely impaired, the muscles develop
congenital myasthenic syndromes. In such disorders, defects
in neuromuscular transmission cause a fatigable weakness
in limb, ocular, bulbar, truncal, and respiratory muscles.
Generally, weakness becomes more severe with exercise and
improves with rest. CMS have been identified worldwide and
occur at a frequency of <1/500,000 people, although this
incidence is constantly growing [80]. Diagnosis can be
difficult, often requiring a high risk of clinical suspicion.
Most patients present symptoms during infancy, although in
some syndromes, symptoms are not manifested until
childhood or adult life. Depending on the neuromuscular
transmission defect, CMS can be classified as presynaptic,
synaptic, or postsynaptic, even though it is not always
possible to identify accurately the cause of the pathology
Fig. 2 The ACh–AChR interaction triggers NMJ assembly negative
signals. Global AChR transcription is inhibited by ACh released by the
nerve. AChR gene transcription suppression occurs through myogenin
inhibition. The myogenic transcription factor myogenin activates muscle-
specific genes including AChRs by binding the E-box element. When the
action potential reaches the axon terminals, it induces the opening of the
voltage-gated Ca2+ channels on the presynaptic nerve membrane. The
Ca2+ influx into the neuron leads synaptic vesicles to fuse with the
presynaptic membrane and to release the neurotransmitter acetylcholine
(ACh) in the synaptic cleft. From here, ACh diffuses and binds to
acetylcoline receptors (AChRs) localized on the postsynaptic membrane
on the muscle fiber. This binding makes AChRs permeable to ions so
that Na+ flows into the fiber while K+ flows out of the muscle cytosol.
In this way, the muscle membrane locally depolarizes, and this local
depolarization opens voltage-gated Na+ channels on the membrane,
allowing a propagation of the depolarization (action potential) that
spreads to involve the entire plasma membrane. The action potential
induced by ACh release leads to the release of Ca2+ from the
sarcoplasmic reticulum into the cytosol which causes muscle contrac-
tion. The high concentration of Ca2+ inside the cytosol also activates
CaMKII and PKC kinases which mediate signaling pathways leading to
myogenin phosphorylation and inactivation. When myogenin is
inactive, AChR expression is suppressed. In addition to myogenin
phosphorylation, a second mechanism, which represses myogenin, is
activated by Ca2+ signaling upon innervation and leads to the activation
of three transcription repressors (MSY-3, DACH2, and HDAC9). These
repressors bind myogenin promoter and inhibit its transcriptional
activation. The binding motifs for MSY-3, DACH2, and HDAC9
(respectively HCE, SIX, and MEF2) are located on adjacent sequences
on the myogenin promoter
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[81]. Over the past few years, many causative genes and
mutations for CMS have been identified, although in many
patients, no causative mutations can be found. In most cases,
CMS causative mutations are missense, truncation, or splice-
site mutations and result in structural changes of AChRs or
in AChR low affinity for ACh. CMS-associated genetic
mutations have been mapped in AChR subunits, choline
acetyltransferase, the collagen tail subunit of acetylcholines-
terase, rapsyn, MuSK, and skeletal muscle–sodium channel
Na1.4 [82–84].
Dok-7 CMS is a newly identified synaptopathy charac-
terized by a “limb girdle” phenotype that mainly affects
proximal muscles rather than the distal ones with ptosis
present from early age [85]. Mutations in the Dok-7 locus
were identified in groups of patients who had small EPs, a
reduced number of AChRs at the EPs, and a limb-girdle
phenotype with no mutations in rapsyn or AChRs. Dok-7
mutants generally have abnormally small and simplified
NMJs but show normal AChR and AChE functions, correct
MuSK activation, and AChR clusterization, although Dok-
7 acts in concert with MuSK in activating rapsyn to
concentrate AChRs at the junctional folds. It has therefore
been suggested that the altered size and integrity of NMJs
observed were probably the consequence of a high and
widespread degeneration and remodeling of the EPs [86, 87].
Together with genetic alterations in the coding region of
components of the synaptic apparatus, also mutations in
their regulative regions can account for the congenital
myasthenic phenotype. A mutation in the N-box of the
AChRε subunit promoter, resulting in a decreased GABP
transcription factor binding activity [88], causes a reduction
in the AChR number which is the cause of CMS clinical
symptoms in human [89, 90].
Besides being congenital, myasthenia can also be caused
by a complex autoimmune disorder of neuromuscular
transmission (myasthenia gravis, MG). MG is characterized
by a fluctuating weakness of the head, neck, and upper
extremity muscles that worsens with activity and improves
with rest [91, 92]. When the bulbar and the respiratory
muscle deteriorate, the disease becomes life-threatening,
and ventilation with medication is required. Approximately
80% of MG patients have autoantibodies against AChR
and, consequently, they show a decreased number of
AChRs at the postynaptic membrane [93]. In addition, the
deposit of the complement causes a structural and func-
tional damage of the postsynaptic membrane, resulting in a
neuromuscular transmission failure. In some MG patients,
autoantibodies against MuSK have also been found, but
their pathogenic role remains unclear since the number of
AChRs is not reduced and no deposits of complement are
found at the postsynaptic membrane. It has been therefore
suggested that, since MuSK can be required for retrograde
signal, it is possible that MuSK autoantibodies interfere
with the presynaptic apparatus organization [94, 95]. Some
other MG patients have autoantibodies to Lrp4, which
inhibit Lrp4 function [96].
5 NMJ degeneration in sarcopenia
The age-related muscle loss (sarcopenia) strongly impairs
the quality of life in the elderly, and it is associated with
increased risk of morbidity and mortality [97]. The etiology
of sarcopenia is not clear yet. However, many studies
suggest that NMJ structural and functional impairment
plays a key role in muscle wasting during aging. NMJ
degeneration is a feature of sarcopenia, and it has been
documented both in animal models and in humans.
Changes in NMJ morphology depend on the type of muscle
and include variation of the nerve terminal area size, of the
end plate size, of the number of synaptic vesicles, of
mitochondrial content, and of smooth endoplasmic reticu-
lum content (reviewed in [98]). By in vivo live animal
imaging, it has been revealed that at 12–18 months, in
mice, a few NMJs start to display loss of motor neuron
terminal branches and AChRs. At this point, probably in
order to compensate for loss of some synaptic sites, motor
neuron sprouting increases and accounts for the formation
of new NMJs. However, this compensatory effect strongly
decreases after 18 months of age. Moreover, the newly
formed synapses are more sensitive to degenerative
changes. Therefore, by 24–36 months, most NMJs are
completely denervated, and postsynaptic EPs are highly
fragmented [98].
Many mechanisms have been evoked as cause of NMJ
degeneration during aging. Age-related changes in the
morphology of NMJs can be related to alteration of the
axonal transport, which impairs the availability of trophic
factors and organelles, such as mitochondria, essential for
neuronal survival [99]. Age-related changes in myelinated
Schwann cells have also been reported and might be
associated with NMJ degeneration [100]. It has interestingly
been shown that neurotrophic and myotrophic factors such as
BDNF, NT-3, insulin-like growth factor (IGF)-I, and IGF-II,
which are necessary for the maintenance of presynaptic and
postsynaptic apparatus at the NMJ, also play a modulating
role in aging [101, 102]. For example, IGF-1 injections into
muscle inhibit motor neuron and NMJ degeneration and
prevent age-related force decline in mice [103].
Recent studies suggest that motor neuron degeneration
and consequent denervation of myofibers are a major cause
of muscle mass loss [104, 105]. In aged people, muscle
fibers undergo cycles of denervation and innervation.
During these cycles, some myofibers are lost, and others,
which were innervated by fast motor neurons (type II
fibers), are reinnervated by slow ones (type I fibers). This
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results in an increased percentage of type I fibers and
atrophy, which characterizes sarcopenia. It has also been
demonstrated that chronic exercise training and higher
neuromuscular activity counteract the alterations in motor
neurons and delay the onset of denervation and sarcopenia
in aged people [104–106].
Although the causes of age-associated NMJ degeneration
remain unclear, other mechanisms might contribute to
compromised muscle neurotransmission and sarcopenia in
aging. For example, sarcopenia is also characterized by
mitochondrial dysfunctions. Presynaptic terminals and post-
synaptic EPs contain a high concentration of mitochondria,
which are critical for NMJ function since they account for
energy support, Ca2+ buffering, synaptic transmission, and
apoptosis [107]. Mitochondrial dysfunctions might lead to
altered calcium buffering, less ATP generation and more
ROS production, and oxidative damage during aging, which
impairs NMJs [108, 109]. In particular, the impaired
buffering of Ca2+ determines an increased concentration of
cytosolic Ca2+, which might activate some proteases called
calpains. It has been shown that calpains interact with rapsyn
thereby disrupting AChR clusters. Through this mechanism,
mitochondrial impairment might partially account for the
age-related dispersion of AChR clusters [110]. Moreover, a
direct correlation between increased oxidative stress and
neuromuscular function has been recently proposed. Mice
lacking the antioxidant enzyme CuZnSOD (Cu/Zn superoxide
dismutase, Sod 1) show high oxidative damage and
rapid sarcopenia. The morphology of NMJs at 11 months
in Sod1−/−mice is altered, and it is comparable to NMJ
degeneration in 33-month-old, wild-type mice. Furthermore,
denervated NMJs and fragmentated AChRs observed in
young Sod1−/−mice notably reduce muscle contractile force
[111, 112]. These observations suggest that NMJ degenera-
tion during aging might be caused also by age-related
oxidative stress, which usually is produced by mitochondrial
dysfunctions. Oxidative stress also induces damage in
myelinated peripheral nerves and consequent increased
inflammatory cytokines during aging (Reviewed in [98]).
Interestingly, it has been recently reported that calorie
restriction slows down the aging process and, in particular,
decreases deterioration of peripheral nerve by upregulating
autophagy [113]. It has also been shown that calorie
restriction reduces oxidative damage, NMJ degeneration,
and muscle atrophy in Sod1−/−mice ,and this further
suggests that oxidative damage affects NMJs [111, 114].
6 Conclusions and prospects
The complexity of the neuromuscular junction apparatus
and of the regulative systems responsible for its organiza-
tion indicates that the functional modulation of the
connection between neurons and muscle fibers is crucial.
The right concentration of the acetylcholine receptors in the
area where the axon terminals juxtaposes the postsynaptic
membrane accounts for the NMJ’s ability to generate the
action potential that provokes muscle contraction and
consequently movements. For this reason, multiple levels
of regulation are committed to accurately control this
process. Animal models show that impairing only one of
these regulative pathways can cause severe phenotypes
characterized by compromised coordinate movements and
breath capacity which usually prove fatal. We have also
seen that transcriptional control plays an important role in
muscle physiological response to nerve activity. CMS and
myasthenia gravis are human pathologies characterized by an
extreme fatigability and muscle weakness and in which
insufficiency of a single component of NMJ frequently
accounts for their pathophysiology. Studying NMJ transmis-
sion in aging and in those pathological conditions characterized
by different levels of muscle weakness may reveal new
mechanisms that contribute to the fine-tuning of the interplay
between motor neurons and muscles. Understanding the
mechanisms underlying age- and disease-associated atrophy
and alteration of NMJs should open up new potential
therapeutic avenues to these skeletal muscle dysfunctions.
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